Amryt to delist from AIM, concentrate on Nasdaq trading
22nd Nov 2021 11:37
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced its intention to cancel its shares from trading on AIM on Monday, with effect on 11 January.
Read moreAmryt Pharma granted another two US patents
19th Oct 2021 15:54
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate 'Oleogel-S10' on Tuesday, as well as its recently-acquired and third commercial product 'Mycapssa'.
Read moreRecord second quarter sees Amryt lift guidance further
6th Aug 2021 12:02
(Sharecast News) - Amryt Pharma reported record second quarter results on Friday, raising its full-year guidance, as revenue in the three months ended 30 June came in at $62.8m, up from $46.2m year-on-year.
Read moreCathal Friel-led Poolbeg Pharma set to float on AIM
17th Jun 2021 14:34
(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.
Read moreFDA grants Amryt's Oleogel-S10 priority review status
3rd Jun 2021 11:26
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).
Read moreAmryt completes rolling FDA submission for Oleogel-S10
31st Mar 2021 11:50
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).
Read moreAmryt releases data from Italy lomitapide study
30th Mar 2021 12:11
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma released efficacy and safety data from the 'Lochnes' investigator-sponsored study of lomitapide in familial chylomicronemia syndrome (FCS) on Tuesday, which was conducted by expert lipidologists in Italy.
Read moreEuropean approval for Amryt's Oleogel-S10 moves closer
29th Mar 2021 09:15
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the validation of its marketing authorisation application for 'Oleogel-S10' by the European Medicines Agency on Monday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa.
Read moreAmryt upbeat on positive FDA feedback
23rd Mar 2021 09:34
(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma has received further feedback from the United States Food and Drug Administration (FDA) on Myalept, it said on Tuesday, and its proposed development plan and study design to support an indication for patients with partial lipodystrophy (PL).
Read moreAmryt's Myalepta gets reimbursement approval in France
22nd Mar 2021 09:04
(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced on Monday that the French Ministry of Social Affairs and Health has approved 'Myalepta', or metreleptin, for reimbursement in the country as an adjunct to diet as replacement therapy.
Read moreDirector dealings: Amryt Pharma chairman makes share purchase
15th Mar 2021 16:38
(Sharecast News) - Amryt Pharma revealed on Monday that chairman Ram Stafford had acquired 300,100 ordinary shares in the AIM-listed commercial-stage biopharmaceutical company.
Read moreAmryt Pharma signs another distribution deal with Medison
8th Mar 2021 12:19
(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the signing of a distribution agreement with Medison Pharma to distribute 'Myalepta' in Canada on Monday.
Read moreAmryt signs multi-regional distribution deals with Medison
4th Feb 2021 14:18
(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced the signing of multi-regional distribution agreements with Medison Pharma on Thursday.
Read moreAmryt gets reimbursement approval for 'Lojuxta' in Saudi Arabia
17th Dec 2020 13:38
(Sharecast News) - Biopharmaceutical company Amryt announced on Thursday that Ministry of Health reimbursement approval has been granted for 'Lojuxta', or lomitapide, in Saudi Arabia.
Read moreAmryt Pharma gets approval for 'Lojuxta' in Brazil
9th Dec 2020 09:47
(Sharecast News) - Biopharmaceutical company Amryt Pharma announced on Wednesday that it has received marketing authorisation approval from the Brazilian Health Regulatory Agency (ANVISA) for 'Lojuxta', or lomitapide.
Read more